



PRESS RELEASE

Particle Sciences to Chair Session and Present on its SATx™ Technology at the 249th American Chemical Society National Meeting

BETHLEHEM, PA, February 23, 2015 - Particle Sciences, Inc (PSI), the leading CDMO for advanced drug delivery technologies will be chairing a session at the ACS National Meeting in Denver on March 24, 2015 addressing protein conjugates and presenting on its newly launched decorated nanoparticle biopharmaceutical platform: Surface Arrayed Therapeutics™, SATx™. Dr. Bob Becker, VP of Biologics Sales and Business Development will discuss SATx™ in a talk entitled: *Nanoparticle Formulations Linking Pharmaceutical Components by Electrostatic and Hydrophobic Binding: A Faster and More Flexible Alternative to ADC's*. Dr. Becker states "Nanoparticles with engineered interiors and surfaces can non-covalently "link" large biopharmaceuticals and small molecule pharmaceuticals forming effective targeted delivery vehicles: for instance, a chemotherapeutic combined with a tumor specific antibody. Like the traditional ADC approach, SATx™ associates antigen-specific antibodies and small molecules but, in contrast to ADC's, enables a far more tunable drug-to-antibody ratio without problematic conjugation chemistries. SATx™ will be capable delivering a far broader range of pharmaceuticals than has been possible with typical ADC approaches and promises to be effective even for disease targets with low antigen copy numbers on their surfaces. The elimination of conjugation chemistries should also reduce regulatory burden for targeted drug delivery and, when applied to vaccines, can improve potency and safety." Additionally, Dr. Robert W. Lee, VP Pharmaceutical Development Services, will be chairing a session on "Protein Conjugates: From Basic Principles to Clinically Active Drug". According to Dr. Lee, "SATx™ leverages PSI's core strengths in surface chemistry and particle fabrication. We are very excited to add this technology to our solution set for our Biopharmaceutical clients."

Particle Sciences is an integrated provider of drug development services. Particle Sciences works with BCS II/III/IV molecules, biologics and highly potent compounds using a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.